Millennium Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.1M | Buy |
882,097
+211,669
| +32% | +$2.84M | ﹤0.01% | 2069 |
|
|
2025
Q4 | $10.6M | Sell |
670,428
-277,656
| -29% | -$3.53M | ﹤0.01% | 2209 |
|
|
2025
Q3 | $11.3M | Sell |
948,084
-510,509
| -35% | -$4.08M | ﹤0.01% | 2272 |
|
|
2025
Q2 | $11M | Buy |
1,458,593
+111,661
| +8% | +$672K | 0.01% | 2165 |
|
|
2025
Q1 | $7.44M | Buy |
1,346,932
+449,945
| +50% | +$2.78M | ﹤0.01% | 2472 |
|
|
2024
Q4 | $5.16M | Buy |
896,987
+165,692
| +23% | +$1.59M | ﹤0.01% | 2794 |
|
|
2024
Q3 | $7.58M | Buy |
731,295
+48,152
| +7% | +$630K | ﹤0.01% | 2454 |
|
|
2024
Q2 | $8.86M | Sell |
683,143
-23,105
| -3% | -$312K | ﹤0.01% | 2194 |
|
|
2024
Q1 | $12.3M | Sell |
706,248
-58,893
| -8% | -$779K | 0.01% | 1995 |
|
|
2023
Q4 | $7.2M | Sell |
765,141
-257,982
| -25% | -$2.4M | ﹤0.01% | 2482 |
|
|
2023
Q3 | $11.4M | Buy |
1,023,123
+789,636
| +338% | +$12.7M | 0.01% | 1921 |
|
|
2023
Q2 | $5M | Buy |
233,487
+92,704
| +66% | +$2.73M | ﹤0.01% | 2672 |
|
|
2023
Q1 | $5.69M | Buy |
140,783
+84,700
| +151% | +$4.04M | ﹤0.01% | 2491 |
|
|
2022
Q4 | $2.61M | Buy |
56,083
+18,499
| +49% | +$843K | ﹤0.01% | 3342 |
|
|
2022
Q3 | $1.95M | Buy |
37,584
+14,648
| +64% | +$856K | ﹤0.01% | 3764 |
|
|
2022
Q2 | $1.08M | Sell |
22,936
-42,797
| -65% | -$2.32M | ﹤0.01% | 4288 |
|
|
2022
Q1 | $4.68M | Buy |
65,733
+49,901
| +315% | +$3.25M | ﹤0.01% | 3009 |
|
|
2021
Q4 | $1.18M | Buy |
15,832
+331
| +2% | +$26K | ﹤0.01% | 4256 |
|
|
2021
Q3 | $881K | Sell |
15,501
-125,241
| -89% | -$6.19M | ﹤0.01% | 4820 |
|
|
2021
Q2 | $6.19M | Buy |
140,742
+116,897
| +490% | +$5.72M | ﹤0.01% | 2474 |
|
|
2021
Q1 | $1.18M | Sell |
23,845
-152,924
| -87% | -$7.63M | ﹤0.01% | 4059 |
|
|
2020
Q4 | $7.44M | Buy |
176,769
+50,856
| +40% | +$2.24M | 0.01% | 2073 |
|
|
2020
Q3 | $5.76K | Buy |
125,913
+89,026
| +241% | +$4.31M | 0.01% | 1710 |
|
|
2020
Q2 | $1.85M | Sell |
36,887
-43,296
| -54% | -$2.24M | ﹤0.01% | 2595 |
|
|
2020
Q1 | $4.12M | Buy |
80,183
+42,751
| +114% | +$2.28M | 0.01% | 1475 |
|
|
2019
Q4 | $2.31M | Buy |
37,432
+31,811
| +566% | +$1.97M | ﹤0.01% | 2524 |
|
|
2019
Q3 | $337K | Sell |
5,621
-59,731
| -91% | -$4.44M | ﹤0.01% | 3497 |
|
|
2019
Q2 | $5.51M | Sell |
65,352
-90,618
| -58% | -$8.15M | 0.01% | 1692 |
|
|
2019
Q1 | $14.9M | Buy |
155,970
+135,325
| +655% | +$12.1M | 0.02% | 989 |
|
|
2018
Q4 | $1.46M | Buy |
+20,645
| New | +$1.58M | ﹤0.01% | 2392 |
|
|
2018
Q3 | – | Sell |
-4,246
| Closed | -$492K | – | 3995 |
|
|
2018
Q2 | $492K | Sell |
4,246
-86,070
| -95% | -$8.59M | ﹤0.01% | 3172 |
|
|
2018
Q1 | $7.31M | Sell |
90,316
-130,529
| -59% | -$10M | 0.01% | 1556 |
|
|
2017
Q4 | $13M | Buy |
+220,845
| New | +$11.1M | 0.02% | 1159 |
|
|
2017
Q3 | – | Sell |
-487,405
| Closed | -$17.5M | – | 3589 |
|
|
2017
Q2 | $17.5M | Buy |
487,405
+46,504
| +11% | +$1.49M | 0.03% | 740 |
|
|
2017
Q1 | $13.6M | Buy |
440,901
+346,127
| +365% | +$10.8M | 0.02% | 865 |
|
|
2016
Q4 | $3.17M | Sell |
94,774
-67,344
| -42% | -$1.93M | 0.01% | 1618 |
|
|
2016
Q3 | $4.31M | Buy |
162,118
+119,608
| +281% | +$2.78M | 0.01% | 1427 |
|
|
2016
Q2 | $937K | Buy |
+42,510
| New | +$1.11M | ﹤0.01% | 2202 |
|
|
2015
Q2 | – | Sell |
-266,927
| Closed | -$8.17M | – | 3450 |
|
|
2015
Q1 | $8.17M | Buy |
266,927
+256,927
| +2,569% | +$10M | 0.02% | 1138 |
|
|
2014
Q4 | $509K | Sell |
10,000
-46,813
| -82% | -$2.1M | ﹤0.01% | 2972 |
|
|
2014
Q3 | $2.25M | Buy |
56,813
+51,398
| +949% | +$2.05M | 0.01% | 1793 |
|
|
2014
Q2 | $233K | Buy |
+5,415
| New | +$207K | ﹤0.01% | 3030 |
|
|
2014
Q1 | – | Sell |
-107,519
| Closed | -$2.93M | – | 3559 |
|
|
2013
Q4 | $2.93M | Buy |
+107,519
| New | +$2.61M | 0.01% | 1545 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
Millennium Management's ENTA Position: Q1 2026 in Review
Millennium Management increased its Enanta Pharmaceuticals (ENTA) stake by 32% in Q1 2026, buying an estimated $2.84M and bringing the position to 882,097 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2069.
Millennium Management first reported a position in ENTA in Q4 2013 and has held it in 43 quarters since. The position peaked at $17.5M in Q2 2017. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Millennium Management held 882,097 shares of Enanta Pharmaceuticals worth $11.1M as of Q1 2026.
- Millennium Management bought 211,669 Enanta Pharmaceuticals shares in Q1 2026, an estimated $2.84M.
- Enanta Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2069 holding.
- Millennium Management first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 43 quarters since.
- Millennium Management's Enanta Pharmaceuticals position peaked at $17.5M in Q2 2017.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.